FDA ap­proves Apel­lis' reti­nal dis­ease drug as com­peti­tor ex­pects Au­gust de­ci­sion

The FDA ap­proved Apel­lis Phar­ma­ceu­ti­cals’ drug for ge­o­graph­ic at­ro­phy sec­ondary to age-re­lat­ed mac­u­lar de­gen­er­a­tion af­ter push­ing back the green light de­ci­sion by three months to go through more da­ta.

The biotech will mar­ket the drug as Syfovre. Known in­ves­ti­ga­tion­al­ly as pegc­eta­coplan in­jec­tion, Apel­lis al­ready mar­kets a ver­sion of the drug as Em­paveli for the rare dis­ease parox­ys­mal noc­tur­nal he­mo­glo­bin­uria.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER